Evolocumab Beats Zetia for LDL Cholesterol
(MedPage Today) -- The first phase III results for Amgen's investigational anti-PCSK9 human monoclonal antibody -- evolocumab -- indicate the drug performed better than placebo and ezetimibe (Zetia), the company announced Tuesday. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 18, 2013 Category: Cardiology Source Type: news
2014: The Year for Ezetimibe and More?2014: The Year for Ezetimibe and More?
While awaiting the delayed IMPROVE-IT trial, what's a physician to do with patients taking ezetimibe? Dr Walton-Shirley ponders this dilemma and the future of surrogate-end-point trials. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 12, 2013 Category: Consumer Health News Tags: Cardiology Blog Source Type: news
Lipid Management with Statins/Ezetimibe Proposed for Chronic Kidney Disease (FREE)
By Joe Elia
The Kidney Disease: Improving Global Outcomes (KDIGO) group is recommending that patients with chronic kidney disease receive lipid management with either statins alone or … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 10, 2013 Category: Primary Care Source Type: news
Sanofi and Regeneron report positive top-line results with alirocumab from first Phase 3 study of a PCSK9 inhibitor for LDL cholesterol reduction
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint. The mean low-density lipoprotein-cholesterol (LDL-C, or "bad" cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab, as compared to patients randomized to ezetimibe (47.2% vs. 15... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 18, 2013 Category: Consumer Health News Tags: Cholesterol Source Type: news
New Monoclonal Antibody Nabs LDL
(MedPage Today) -- The monoclonal antibody alirocumab, a PCSK9 inhibitor, significantly reduced LDL cholesterol when compared with ezetimibe (Zetia) in a phase III trial, top-line results released by the drug makers showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 17, 2013 Category: Cardiology Source Type: news
PCSK9 Inhibitor Beats Ezetimibe for LDL LoweringPCSK9 Inhibitor Beats Ezetimibe for LDL Lowering
The monoclonal antibody targeting PCSK9 alirocumab significantly reduced LDL-cholesterol levels when compared with ezetimibe in patients with hypercholesterolemia. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Liptruzet: Why Prescribe It?Liptruzet: Why Prescribe It?
Dr. Howard Weintraub discusses the recent approval of Liptruzet, the atorvastatin/ezetimibe combination used to treat elevated LDL-cholesterol levels. Medscape Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 13, 2013 Category: Consumer Health News Tags: Cardiology Expert Interview Source Type: news
Liptruzet (ezetimibe and atorvastatin) for the Treatment of Hyperlipidaemia
Liptruzet (ezetimibe and atorvastatin) is a combination drug indicated to reduce elevated low-density lipoprotein (LDL) cholesterol in patients suffering from hyperlipidaemia disorder. (Source: Drug Development Technology)
Source: Drug Development Technology - June 5, 2013 Category: Pharmaceuticals Source Type: news
Liptruzet (Ezetimibe and Atorvastatin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 17, 2013 Category: Drugs & Pharmacology Source Type: news
The FDA Approval Of Merck's Cholesterol Lowerer, Liptruzet, Doesn't Help Its Credibility
Given this history, what was the FDA thinking in approving another Zetia/statin combination? It is not as if a drug like Liptruzet is desperately needed. After all, there are plenty of statins available that have shown their ability to reduce CV events in long term studies. Furthermore, each component of Liptruzet is already available to physicians and so can be prescribed to be used together, should a physician deem this necessary. Shouldn’t the FDA have waited for the results of Merck’s IMPROVE-IT study before unleashing another such combination? Think of the embarrassment for the FDA should IMPROVE-IT show that th...
Source: Forbes.com Healthcare News - May 10, 2013 Category: Pharmaceuticals Authors: John LaMattina Source Type: news
Liptruzet Approved By FDA To Cut Cholesterol, Despite Criticism By Cardiologists
Liptruzet, a cholesterol-lowering drug that combines Merck's Zetia (ezetimibe) with atorvastatin (generic version of Pfizer's Lipitor) has been approved by the US FDA (Food and Drug Administration). According to Merck and Co, Liptruzet tablets are for the treatment of high LDL (low-density lipoprotein) cholesterol in patients with primary or mixed hyperlipidemia alongside a special diet when diet alone is not enough. Hyperlipidemia is an excessively high concentration of fats (lipids) in the blood... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 5, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
F.D.A. Approves Merck’s Combination Drug to Reduce Cholesterol
The drug pairs Merck’s Zetia, which lowers low-density lipoprotein, with the generic version of Lipitor, the best-selling statin made by Pfizer that lost its patent protection in 2011. (Source: NYT Health)
Source: NYT Health - May 4, 2013 Category: Consumer Health News Authors: By KATIE THOMAS Tags: Pfizer Inc PFE NYSE Drugs (Pharmaceuticals) Food and Drug Administration Zetia (Drug) Cholesterol Lipitor (Drug) Merck & Company Inc MRK NYSE Source Type: news
FDA approves Merck's Liptruzet (atorvastatin/ezetimibe)FDA approves Merck's Liptruzet (atorvastatin/ezetimibe)
The combination, known as Liptruzet, is approved for the treatment of elevated LDL cholesterol levels in patients with primary or mixed hyperlipidemia as an adjunct to dietary changes. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 4, 2013 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
Merck's Cholesterol Pill Win Is Already Drawing Fire
The Food and Drug Administration just approved Liptruzet, a new cholesterol-lowering pill that combines the generically available ingredient available in Pfizer's Lipitor with Merck's Zetia. Merck has been working to get the combination pill approved for several years -- and one critic is already saying it was a mistake to approve the combination drug. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 3, 2013 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
